

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith and Tom Blanchard

Application No.: 10/686,943

Group: 1648

Filed: October 16, 2003

Examiner: Not Yet Assigned

Confirmation No.: 4585

For: Methods and Reagents for Vaccination Which Generate a CD8 T Cell Immune Response

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
7-2-04	<i>[Signature]</i>
Date	Signature
<i>Jeanine Busby</i>	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted:

☐ under 37 CFR 1.129(a), or

(First/Second submission after Final Rejection)

☒ under 37 CFR 1.97(b), or

(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

☐ under 37 CFR 1.97(c) together with either:

☐ a Statement under 37 CFR 1.97(e), as checked below, or

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with:

☐ a Statement under 37 CFR 1.97(e), as checked below, and

☐ a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

☐ under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

☒ Enclosed herewith is form PTO-1449:

☒ Copies of the cited references are enclosed.

☒ Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.

☒ Copies of the cited references are enclosed (AZ, AR3, AV3, AY4, AZ4, AR5, AS5, AX5, AY5, AS6, AT6, AS7, AU7, AV7, AX7, AV8-AZ8, and AR9-AZ9; AR10) except those entered in prior application, U.S. Application No. 09/454,204, to which priority under 35 U.S.C. 120 is claimed. The earlier application contains copies of the cited references.

☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

☐ The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:

☐ the explanation provided on the attached sheet.

☐ the explanation provided in the Specification.

☐ submission of the enclosed International Search Report.

☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

☐ the enclosed English language abstract.

[X] Applicant requests that the following non-published pending applications be considered:

Examiner's  
Initials

_____	U.S. Patent Application No. 10/653,624, by McMichael, A. <i>et al.</i> , filed September 2, 2003, Docket No.: 2907.1000-002
_____	U.S. Patent Application No. 10/833,744, by McMichael, A., <i>eta al.</i> , filed April 28, 2004, Docket No.: 2907.1000-004
_____	U.S. Patent Application No. 10/833,439, by McMichael, A., <i>et al.</i> , filed April 28, 2004, Docket No.: 2907.1000-005
_____	U.S. Patent Application No. 10/833,745, by McMichael, A., <i>et al.</i> , filed April 28, 2004, Docket No.: 2907.1000-006

\_\_\_\_\_  
Examiner

\_\_\_\_\_  
Date

- [ X ] A copy of each above-cited application, including the current claims, is enclosed.
- [ ] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- [ ] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- [ ] Please charge Deposit Account 08-0380 in the amount of \$[ ]. A copy of this Statement is enclosed.
- [X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,


HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By   
Anne J. Collins  
Registration No.: 40,564  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:



PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
 <p><b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b></p> <p>July 2, 2004</p> <p>(Use several sheets if necessary)</p>		APPLICANT Adrian V.S. Hill, <i>et al.</i>			
		FILING DATE October 16, 2003		CONFIRMATION NO. 4585	

## U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	5,110,587	May 5, 1992	Paoletti, <i>et al.</i>
	AB	5,185,146	February 9, 1993	Altenburger
	AC	5,225,336	July 6, 1993	Paoletti
	AD	5,453,364	September 26, 1995	Paoletti
	AE	5,766,597	June 16, 1998	Paoletti, <i>et al.</i>
	AF	6,663,871 B1	December 16, 2003	McMichael, <i>et al.</i>
	AG	US-2003-0138454-A1	July 24, 2003	Hill, <i>et al.</i>
	AH			
	AI			
	AJ			
	AK			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	AL	WO 97/39771	October 30, 1997	The Gov. of the U.S.		
	AM	WO 98/04728	February 5, 1998	Therion Biologics Corporation		
	AN	WO 96/26271	August 29, 1996	Therion Biologics Corporation		
	AO					
	AP					
	AQ					

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. <b>2907.1000-003</b>	APPLICATION NO. <b>10/686,943</b>	
	APPLICANT <b>Adrian V.S. Hill, et al.</b>		
	FILING DATE <b>October 16, 2003</b>	CONFIRMATION NO. <b>4585</b>	GROUP <b>1648</b>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR	Ada, G., "Do Cytotoxic T Lymphocytes Clear Some HIV/SIV Infections?," <i>J. Med. Primatol.</i> 25(3):158-162 (June 1996).	
AS	Aidoo, M., <i>et al.</i> , "Identification of Conserved Antigenic Components For a Cytotoxic T Lymphocyte-Inducing Vaccine Against Malaria," <i>Lancet</i> 345(8956):1003-1007 (Apr. 22, 1995).	
AT	Aidoo, M., <i>et al.</i> , "Recombinant Vaccinia Viruses for the Characterization of <i>Plasmodium falciparum</i> -specific Cytotoxic T Lymphocytes: Recognition of Processed Antigen Despite Limited Re-Stimulation Efficacy," <i>Intl. Immunol.</i> 9(5):731-737 (Jan. 1997).	
AU	Allsopp, C.E.M., <i>et al.</i> , "Comparison of Numerous Delivery Systems for the Induction of Cytotoxic T Lymphocytes By Immunization," <i>Eur. J. Immunol.</i> 26:1951-1959 (1996).	
AV	Blanchard, T., <i>et al.</i> , "Future Vaccines for HIV," <i>Lancet</i> 348(9043):1741 (Dec. 1996).	
AW	Blanchard, T.J., <i>et al.</i> , "Modified Vaccinia Virus Ankara Undergoes Limited Replication in Human Cells and Lacks Several Immunomodulatory Proteins: Implications for Use as a Human Vaccine," <i>J. Gen. Virol.</i> 79:1159-1167 (1998).	
AX	Carroll, M.W., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara (MVA) as an Effective Recombinant Vector: A Murine Tumor Model," <i>Vaccine</i> 15(4):387-394 (1997).	
AY	Chamberlain, R.S., <i>et al.</i> , "Use of Multiple Vaccination Vectors for the Generation of CTL Against a Model Tumor Antigen," <i>Proceedings of the Annual Meeting of the American Association for Cancer Research</i> (Washington, April 20-24, 1996, 37, Abstract No. 3263).	
AZ	Doolan, D.L., "The Complexity of Protective Immunity Against Live-Stage Malaria," <i>J. Immunol.</i> , 165(3):1453-1462 (2000).	
AR2	Doolan, D.L., <i>et al.</i> , "Circumventing Genetic Restriction of Protection against Malaria with Multigene DNA Immunization: CD8 <sup>+</sup> T Cell-, Interferon $\gamma$ -, and Nitric Oxide-Dependent Immunity," <i>J. Exp. Med.</i> 183(4):1739-1746 (April 1996).	
AS2	Fuller, D.H., <i>et al.</i> , "Gene Gun-Based Nucleic Acid Immunization Alone or in Combination with Recombinant Vaccinia Vectors Suppresses Virus Burden in Rhesus Macaques Challenged with a Heterologous SIV," <i>Immunol. Cell Biol.</i> 75(4):389-396 (Aug. 1997).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
	APPLICANT Adrian V.S. Hill, <i>et al.</i>		
	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AT2	Fuller, D.H., <i>et al.</i> , "Enhancement of Immunodeficiency Virus-Specific Immune Responses in DNA-Immunized Rhesus Macaques," <i>Vaccine</i> , 15(8):924-926 (June 1997).	
AU2	Gallimore, A., <i>et al.</i> , "Early Suppression of SIV Replication By CD8 <sup>+</sup> <i>nef</i> -specific Cytotoxic T Cells In Vaccinated Macaques," <i>Nature Med.</i> 1(11):1167-1173 (Nov. 1995).	
AV2	Gilbert, S.C., <i>et al.</i> , "A Protein Particle Vaccine Containing Multiple Malaria Epitopes," <i>Nat. Biotechnol.</i> , 15(12):1280-1284 (1997).	
AW2	Greenspan, N.S., <i>et al.</i> , "Defining Epitopes: It's Not As Easy As It Seems," <i>Nature Biotechnology</i> 7:936-937 (1999).	
AX2	Hanke, T., <i>et al.</i> , "Immunogenicities of Intravenous and Intramuscular Administrations of Modified Vaccinia Virus Ankara-Based Multi-CTL Epitope Vaccine for Human Immunodeficiency Virus Type 1 in Mice," <i>J. Gen. Virol.</i> 79:83-90 (1998).	
AY2	Hanke, T., <i>et al.</i> , "Enhancement of MHC Class I-Restricted Peptide-Specific T Cell Induction by a DNA Prime/MVA Boost Vaccination Regime," <i>Vaccine</i> 16(5):439-445 (1998).	
AZ2	Hanke, T., <i>et al.</i> , "DNA Multi-CTL Epitope Vaccines for HIV and <i>Plasmodium falciparum</i> : Immunogenicity in Mice," <i>Vaccine</i> 16(4):426-435 (1998).	
AR3	Hill, AV, "DNA-Based Vaccines for Malaria: a Heterologous Prime-Boost Immunisation Strategy," <i>Dev. Biol. (Basel)</i> , 104:171-179 (2000).	
AS3	Hill, A.V.S., <i>et al.</i> , "Common West African HLA Antigens Are Associated With Protection From Severe Malaria," <i>Nature</i> 352(6336):595-600 (Aug. 15, 1991).	
AT3	Hirsch, V.M., <i>et al.</i> , "Patterns of Viral Replication Correlate with Outcome in Simian Immunodeficiency Virus (SIV)-Infected Macaques: Effect of Prior Immunization with a Trivalent SIV Vaccine in Modified Vaccinia Virus Ankara," <i>J. Virol.</i> 70(6):3741-3752 (June 1996).	
AU3	Hodge, J.W., <i>et al.</i> , "Diversified Prime and Boost Protocols Using Recombinant Vaccinia Virus and Recombinant Non-Replicating Avian Pox Virus to Enhance T-Cell Immunity and Antitumor Responses," <i>Vaccine</i> 15(6/7):759-768 (April/May 1997).	
AV3	Tascon, R. <i>et al.</i> , "Vaccination Against Tuberculosis by DNA Injection," <i>Nat. Med.</i> 2: 893-898 (1996).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
	APPLICANT Adrian V.S. Hill, <i>et al.</i>		
	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AW3	Irvine, K.R., <i>et al.</i> , "Route of Immunization and the Therapeutic Impact of Recombinant Anticancer Vaccines," <i>J. Natl. Cancer Inst.</i> 89(5):390-392 (March 1997).	
AX3	Irvine, K.R., <i>et al.</i> , "Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regiments That Use Two Different Vectors," <i>J. Natl. Cancer Inst.</i> 89(21):1595-1601 (Nov. 1997).	
AY3	Lalvani, A., <i>et al.</i> , "An HLA-Based Approach to the Design of a CTL-Inducing Vaccine Against <i>Plasmodium falciparum</i> ," <i>Research in Immunology</i> 145(6):461-468 (1994).	
AZ3	Lanar, D.E., <i>et al.</i> , "Attenuated Vaccinia Virus-Circumsporozoite Protein Recombinants Confer Protection against Rodent Malaria," <i>Infect. Immun.</i> 64(5):1666-1671 (May 1996).	
AR4	Layton, F.T., <i>et al.</i> , "Induction of Single and Dual Cytotoxic T-Lymphocyte Responses to Viral Proteins in Mice Using Recombinant Hybrid Ty-Virus-Like Particles," <i>Immunology</i> 87(2):171-178 (Feb. 1996).	
AS4	Leong, K.H., <i>et al.</i> , "Selective Induction of Immune Responses by Cytokines Coexpressed in Recombinant Fowlpox Virus," <i>J. Virol.</i> , 68(12):8125-8130 (Dec. 1994).	
AT4	Leong, K.H., <i>et al.</i> , "Generation of Enhanced Immune Responses by Consecutive Immunization with DNA and Recombinant Fowl Pox Vectors." In <i>Vaccines 95</i> , Cold Spring Harbor Laboratory Press, p.327-331 (1995).	
AU4	Li, Shengqiang, <i>et al.</i> , "Priming With Recombinant Influenza Virus Followed By Administration of Recombinant Vaccinia Virus Induces CD8 <sup>+</sup> T-Cell-Mediated Protective Immunity against Malaria," <i>Proc. Natl. Acad. Sci. USA</i> 90(11):5214-5218 (June 1993).	
AV4	Limbach, K.J. and Paoletti, E., "Non-Replicating Expression Vectors: Application in Vaccine Development and Gene Therapy," <i>Epidemiol. Infect.</i> 116:241-256 (1996).	
AW4	Mahnel, <i>et al.</i> , "Experiences with Immunization Against Orthopox Viruses of Humans and Animals Using Vaccine Strain MVA," <i>Berliner Und Munchener Tierarztliche Wochenschrift</i> 107(8):253-256 (1994) ABSTRACT ONLY	
AX4	McMichael, A., <i>et al.</i> , "Malaria and Other Tropical Diseases," <i>Immunol. Letters</i> 56(1/3):28, 425, 291 (June 22-25, 1997)(Abstract Nos. O.4.05.7, P.4.05.08, P.4.01.18 and P.4.01.22).	

EXAMINER	DATE CONSIDERED
----------	-----------------



PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003		APPLICATION NO. 10/686,943	
	APPLICANT Adrian V.S. Hill, <i>et al.</i>			
	FILING DATE October 16, 2003		CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AY4	McShane, H., <i>et al.</i> , "Enhanced Immunogenicity of CD4 <sup>+</sup> T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis," <i>Infect. Imm.</i> 69(2):681-686 (2001).
	AZ4	Moorthy, M.S., <i>et al.</i> , "Safety of DNA and Modified vaccinia virus Ankara Vaccines Against Liver-Stage <i>P. falciparum</i> Malaria in Non-Immune Volunteers," <i>Vaccine</i> , 21(17-18):1995-2002 (2003).
	AR5	Moorthy, M.S. and Hill, A., "Malaria Vaccines," <i>Br. Med. Bull.</i> , 62:59-72 (2002).
	AS5	Moreno, A., <i>et al.</i> , "Cytotoxic CD4 <sup>+</sup> T Cells From a Sporozoite-Immunized Volunteer Recognize the <i>Plasmodium falciparum</i> CS Protein," <i>Int-Immunol</i> , 3(10):997-1003 (1991).
	AT5	Moss, B., <i>et al.</i> , "Host Range Restricted, Non-Replicating Vaccinia Virus Vectors as Vaccine Candidates," <i>Advances in Experimental Medicine and Biology</i> 397:7-13 (1996).
	AU5	Müller, H.M., <i>et al.</i> , "Thrombospondin Related Anonymous Protein (TRAP) of <i>Plasmodium falciparum</i> Binds Specifically to Sulfated Glycoconjugates and to HepG2 Hepatoma Cells Suggesting a Role for this Molecule in Sporozoite Invasion of Hepatocytes," <i>Embo J.</i> :2881-2889 (July 1993).
	AV5	Murata, K., <i>et al.</i> , "Characterization of <i>in Vivo</i> Primary and Secondary CD8 <sup>+</sup> T Cell Responses Induced by Recombinant Influenza and Vaccinia Viruses," <i>Cell. Immunol.</i> 173(1):96-107 (Oct. 10, 1996).
	AW5	Nardin, E.H. and Nussenzweig, R.S., "T Cell Responses to Pre-Erythrocytic Stages of Malaria: Role in Protection and Vaccine Development Against Pre-Erythrocytic Stages," <i>Annu. Rev. Immunol.</i> 11:687-727 (1993).
	AX5	Plebanski, M., <i>et al.</i> , "Protection From <i>Plasmodium berghei</i> Infection By Priming and Boosting T Cells to a Single Class I-Restricted Epitope with Recombinant Carriers Suitable for Human Use," <i>Eur. J. Immunol.</i> , 28(12):4345-4355 (1998).
	AY5	Richmond, J.F.L., <i>et al.</i> , "Screening of HIV-1 Env Glycoproteins for the Ability to Raise Neutralizing Antibody Using DNA Immunization and Recombinant Vaccinia Virus Boosting," <i>Virology</i> 230:265-274 (1997).
	AZ5	Rodrigues, E.G., <i>et al.</i> , "Single Immunizing Dose of Recombinant Adenovirus Efficiently Induces CD8 <sup>+</sup> T Cell-Mediated Protective Immunity Against Malaria," <i>J. Immunol.</i> 158(3):1268-1274 (Feb. 1997).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. <b>2907.1000-003</b>	APPLICATION NO. <b>10/686,943</b>	
	APPLICANT <b>Adrian V.S. Hill, et al.</b>		
	FILING DATE <b>October 16, 2003</b>	CONFIRMATION NO. <b>4585</b>	GROUP <b>1648</b>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AR6	Rodrigues, M., et al., "Influenza and Vaccinia Viruses Expressing Malaria CD8 <sup>+</sup> T and B Cell Epitopes," <i>J. Immunol.</i> 153(10):4636-4648 (Nov. 15, 1994).	
AS6	Schneider, J., et al., "A Prime-Boost Immunisation Regimen Using DNA Followed By Recombinant Modified Vaccinia Virus Ankara Induces Strong Cellular Immune Responses Against the <i>Plasmodium falciparum</i> TRAP Antigen In Chimpanzees," <i>Vaccine</i> , 19(32):4595-4602 (2001).	
AT6	Schneider, J., et al., "Induction of CD8 <sup>+</sup> T Cells Using Heterologous Prime-Boost Immunisation Strategies," <i>Immunological Reviews</i> , 170:29-38 (1999).	
AU6	Schneider, J., et al., "Enhanced Immunogenicity for CD8 <sup>+</sup> T Cell Induction and Complete Protective Efficacy of Malaria DNA Vaccination by Boosting with Modified Vaccinia Virus Ankara," <i>Nature Medicine</i> 4(4): 397-402 (April 1998).	
AV6	Schödel, F., et al., "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," <i>J. Exp. Med.</i> 180(3):1037-1046 (Sept. 1994).	
AW6	Sedegah, M., et al., "Protection against Malaria by Immunization with Plasmid DNA Encoding Circumsporozoite Protein," <i>Proc. Natl. Acad. Sci. USA</i> 91(21):9866-9870 (Oct. 1994).	
AX6	Seguin, M.C., et al., "Induction of Nitric Oxide Synthase Protects against Malaria in Mice Exposed to Irradiated <i>Plasmodium berghei</i> Infected Mosquitoes: Involvement of Interferon $\gamma$ and CD8 <sup>+</sup> T Cells," <i>J. Exp. Med.</i> 180(1):353-358 (July 1994).	
AY6	Stoute, J.A., et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium falciparum</i> Malaria," <i>NE J. of Medicine</i> 336:86-91 (1997).	
AZ6	Sutter, G., et al., "A Recombinant Vector Derived From the Host Range-Restricted and Highly Attenuated MVA Strain of Vaccinia Virus Stimulates Protective Immunity in Mice to Influenza Virus," <i>Vaccine</i> 12(11):1032-1040 (Aug. 1994).	
AR7	Tartaglia, J., et al., "NYVAC: A Highly Attenuated Strain of Vaccinia Virus," <i>Virology</i> 188(1):217-232 (May 1992).	
AS7	Tascon, et al., "Immunogenicity and Protective Efficacy of a Tuberculosis DNA Vaccine," <i>Nat. Med.</i> 2: 888-892 (1996).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
	APPLICANT Adrian V.S. Hill, <i>et al.</i>		
	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AT7	Tsang, K.Y., <i>et al.</i> , "Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine," <i>J. Natl. Cancer Inst.</i> 87(13):982-990 (July 1995).	
AU7	Tsuji, M., <i>et al.</i> , "CD4 <sup>+</sup> Cytolytic T Cell Clone Confers Protection Against Murine Malaria," <i>J. Exp. Med.</i> , 172(5):1353-1357 (1990).	
AV7	Wang, R., <i>et al.</i> , "Induction of CD4 <sup>+</sup> T Cell-Dependent CD8 <sup>+</sup> Type 1 Responses in Humans By a Malaria DNA Vaccine," <i>PNAS</i> , 98:10817-10822 (2001).	
AW7	Wizel, B., <i>et al.</i> , "Irradiated Sporozoite Vaccine Induces HLA-B8-Restricted Cytotoxic T Lymphocyte Responses against Two Overlapping Epitopes of the <i>Plasmodium falciparum</i> Sporozoite Surface Protein 2," <i>J. Exp. Med.</i> 182(5):1435-1445 (Nov. 1995).	
AX7	Zhu, X., <i>et al.</i> , "Functions and Specificity of T Cells Following Nucleic Acid Vaccination of Mice Against <i>Mycobacterium tuberculosis</i> Infection," <i>J. Immunol.</i> , 158:5921-5926 (1997).	
AY7	Sequence Alignment of SEQ ID NO: 2 with Geneseq database ID NO: AAR43244 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>	
AZ7	Sequence Alignment of SEQ ID NO: 4 with Geneseq database ID NO: AAR43245 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>	
AR8	Sequence Alignment of SEQ ID NO: 6 with Geneseq database ID NO: AAR43243 from WO 93/201103-A. Entry date: May, 1994 Inventor: Elvin, <i>et al.</i>	
AS8	Rodriguez, D., <i>et al.</i> , "Regulated Expression of Nuclear Genes by T3 RNA Polymerase and <i>lac</i> Repressor. Using Recombinant Vaccinia Virus Vectors," <i>J. Virol.</i> 64(10):4851-4857 (Oct. 1990).	
AT8	Watson, J.C., <i>et al.</i> , "General Immunization Practices," Ch. 5, in <i>Vaccines</i> , Plotkin, S.A. and Orenstein, eds., WB Saunders publ. 1999.	
AU8	Drexler, I., <i>et al.</i> , "Highly Attenuated Modified Vaccinia Virus Ankara Replicates in Baby Hamster Kidney Cells, a Potential Host for Virus Propagation, But Not in Various Human Transformed and Primary Cells," <i>J. Gen. Virol.</i> 79:347-352 (1998).	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <b>July 2, 2004</b>  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
	APPLICANT Adrian V.S. Hill, <i>et al.</i>		
	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AV8	Reece, WHH, <i>et al.</i> , "A DNA/MVA Prime-Boost Vaccination Regime Induces Strong Immune Responses and Partial Protection Against <i>Plasmodium falciparum</i> in Humans," <i>Poster at the British Society for Immunology</i> (December 2001).	
AW8	"Peptide Database", Cancer Immunity, March 2001, online, retrieved from the Internet on June 23, 2003. <URL: <a href="http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm">http://cancerimmunity.org/peptidedatabase/tcellepitopes.htm</a> >	
AX8	Zorn, E., <i>et al.</i> , 'A Natural Cytotoxic T Cell Response in a Spontaneously Regressing Human Melanoma Targets a Neoantigen Resulting From a Somatic Point Mutation,' <i>Eur. J. Immunol.</i> , 29:592-601 (1999).	
AY8	Rimoldi, D., <i>et al.</i> , 'Efficient Simultaneous Presentation of NY-ESO-1/LAGE-1 Primary and Nonprimary Open Reading Frame-Derived CTL Epitopes in Melanoma,' <i>J. Immunol.</i> , 165:7253-7261 (2000).	
AZ8	Castelli, C., <i>et al.</i> 'Mass Spectrometric Identification of a Naturally Processed Melanoma Peptide Recognized by CD8 <sup>+</sup> Cytotoxic T Lymphocytes', <i>J. Exp. Med.</i> , 181:363-368 (1995).	
AR9	Ohminami, H., <i>et al.</i> , 'HLA Class I-Restricted Lysis of Leukemia Cells by a CD8 <sup>+</sup> Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide,' <i>Blood</i> , 95:286-293 (2000).	
AS9	'Epitope Maps', HIV Molecular Immunology Database, online, retrieved from the Internet on June 23, 2003. <URL: <a href="http://hiv-web.lanl.gov/content/immunology/maps/maps.html">http://hiv-web.lanl.gov/content/immunology/maps/maps.html</a> >	
AT9	SYFPEITHI Database, 'Find Your Motif, Ligand or Epitope,' <URL: <a href="http://syfpeithi.bmiheidelberg.com/Scripts/MHCServer.dll/findyourmotif.htm">http://syfpeithi.bmiheidelberg.com/Scripts/MHCServer.dll/findyourmotif.htm</a> >	
AU9	Egan, M.A., <i>et al.</i> , "Induction of Human Immunodeficiency...", <i>Concise Communications</i> , 171:1623-1627, 1995	
AV9	Wang, M., <i>et al.</i> , "Active Immunotherapy of Cancer...", <i>The American Association of Immunologists</i> , p. 4685-4692, 1995	
AW9	Tartaglia, J., <i>et al.</i> , "Protection of Cats against Feline...", <i>Journal of Virology</i> , p. 2370-2375, 1993	
AX9	Brossart, P., <i>et al.</i> , "Virus-Mediated Delivery of Antigenic...", <i>The American Association of Immunologists</i> , p. 3270-3276, 1997	

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  July 2, 2004  (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2907.1000-003	APPLICATION NO. 10/686,943	
	APPLICANT Adrian V.S. Hill, <i>et al.</i>		
	FILING DATE October 16, 2003	CONFIRMATION NO. 4585	GROUP 1648

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AY9	Chamberlain, R.S., Poster Presentation presented at the Meeting of the American Association of Cancer Research, April 20 <sup>th</sup> through April 24 <sup>th</sup> , 1996.
	AZ9	Irvine, K., <i>et al.</i> , "Comparison of a CEA-Recombinant Vaccinia...", <i>Vaccine Research</i> , 2(2):79-94, 1993
	AR10	Franchini, G., <i>et al.</i> , "Highly Attenuated HIV Type 2...", <i>AIDS Research and Human Retroviruses</i> , 11(8):909-920, 1995

EXAMINER	DATE CONSIDERED
----------	-----------------